USA flag logo/image

An Official Website of the United States Government

RNA Amplification for Diagnostic Microarrays

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
89212
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
GM084556
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AMBION DIAGNOSTICS, INC.
Asuragen, Inc. 2150 WOODWARD ST AUSTIN, TX -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2009
Title: RNA Amplification for Diagnostic Microarrays
Agency: HHS
Contract: 2R44GM084556-02
Award Amount: $1,162,790.00
 

Abstract:

DESCRIPTION (provided by applicant): The overall goal of this proposal is to develop and implement an integrated suite of technologies for enabling microarray-based diagnostic assays and the cGMP manufacturing processes and procedures necessary to manufact ure these products. Microarrays have found widespread use in biology and medicine as important tools for evaluating gene expression and genomics. Using these tools, clinical researchers are driving the characterization of the molecular signatures of diseas e as they relate to both prognosis and therapy. By resolving the detection of complex analyte mixtures, microarray technology offers tremendous promise to improve patient care in situations in which clinical decisions must be informed by classifiers based on inputs from large sets of features. Broader implementation of diagnostic microarrays will require the development and manufacture of enabling technologies that are robust and reproducible and can be performed reliably and efficiently in the clinical dia gnostic laboratory setting. Rigorous control of design and manufacturing processes of these products is essential to achieving inter-lot, inter-laboratory consistency and obtaining regulatory approval and reimbursement. The solutions to these issues should enable much more widespread implementation of diagnostic microarrays and the corresponding advances in human healthcare that are promised by molecular diagnostics. Phase I activities have resulted in the development of a cGMP manufactured, single-tube, st reamlined amplification format that shows excellent correlation with industry- standard research-grade amplification reagents. This Phase II application outlines the steps we will take to expand features of this product to be the most comprehensive amplifi cation format. The investigations in this grant will be directed toward the development of a thorough set of quality control features and assays that will give information suitability of the reagents for microarray outcomes. PUBLIC HEALTH RELEVANCE: As und erstanding of human disease progresses and new methods for high throughput analyses continue to be developed, molecular diagnostics testing is becoming more accurate but more complicated. Our investigations will provide quality and control tools to ensure that these diagnostic tests can be used in clinical laboratories.

Principal Investigator:

Justin T. Brown

Business Contact:

Andruss Bernard
bandruss@asuragen.com
Small Business Information at Submission:

AMBION DIAGNOSTICS, INC.
Asuragen, Inc. 2150 WOODWARD ST AUSTIN, TX 78744

EIN/Tax ID: 043832139
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No